Specimen Collection Cards Market Report

Increasing advances in non-invasive procedures and the rising prevalence of infectious diseases worldwide have augmented the need for diagnostic tools for laboratory analysis. For instance, according to the Department of Biotechnology (DBT), infectious diseases are among the top ten causes of death in the population, and it is estimated by a WHO report that around 704 million individuals are associated with different pathogens, including 309 million children less than 5 years of age. Consequently, with rising awareness about early medical intervention and regular diagnostic testing, limited access to traditional on-site blood sample collection laboratories, healthcare and research facilities, and the absence of reliable transportation in remote areas have led to advances in the healthcare field in adopting more remote healthcare options. Many market players are introducing novel and innovative methods in self-diagnostic testing tools and propelling the specimen collection cards market growth.  

For instance, in January 2024, ClinicSciences, in collaboration with Trajan Scientific, offered an expansion of the microsampling devices market of Hempen and Mitra in France, Italy, Spain, and Portugal, enabling anyone to collect blood samples even at home by following instructions provided in the sampling kit, making it ideal for blood sugar tests and infectious disease tests suited to both professionals and laypeople. In addition, many self-diagnostic tools monitoring for infectious diseases such as non-variola orthopoxviral, monkeypox, and human papillomavirus are present in the market that allow minimally invasive methods and easy specimen collection features, helping in decentralized clinical trials in remote areas also. For instance, in April 2024, Labcorp received FDA emergency use approval for the Mpox PCR Test Home Collection Kit for diagnosis of non-variola orthopoxviral infection and monkeypox virus in older patients. The diagnostic kit works on the principle of PCR technology, with a return laboratory package for disease analysis. Providing crucial diagnostic tools and convenient testing options to patients and physicians, and increasing the demand for specimen collection cards market.

 
In addition, Abbott launched the Cervi-Collect Specimen Collection Kit for HPV testing, using cervical canal samples containing a cervical brush and transport tube to stabilize DNA, allowing simplified sample collection using an automated sample preparation system, helping to reduce manual steps and sampling errors, allowing less time consumption and minimum resource requirement to maintain the integrity of the sample. The increasing preference for specimen collection card testing is helping the market to grow, positively influencing the specimen collection cards market size.

The rapidly changing technological landscape is increasing the demand for safer and more efficient diagnostic procedures aimed at improving patient diagnostic outcomes to reduce invasive procedures for diseases such as idiopathic pulmonary fibrosis. According to the National Institute of Health (NIH), the prevalence of IPF in older individuals is approximately 85%, and per 10,000 individuals, 10.7% of cases are in males and 7.4% of cases are in females. To reduce the number of invasive procedure cases, many specimen collection card companies are stepping up to the plate by offering innovative and practical solutions to patients by using AI-powered tools and software. For instance, in January 2024, the FDA approved Fibresolve, an artificial intelligence diagnostic tool for early detection and intervention of high-risk patients by identifying patterns of idiopathic fibrosis and CT scan analysis. It is mainly used to provide timely and personalized treatment, acting as an auxiliary tool for clinics by preventing the need for invasive and expensive testing.

Furthermore, AI technology is attributed to the rise in awareness about early medical intervention through cognitive tests for dementia, Alzheimer's, and other impairments. According to WHO, more than 55 million people have dementia, and around 60% are in low- and high-income countries. Alzheimer's contributes around 60-70% of the cases; to reduce the cases of memory loss conditions in the population, many market players are developing innovative software that helps in early diagnosis. For instance, in January 2024, the FDA approved Brainsee, an AI-powered software platform that uses scores from standard cognitive tests and MRI data to predict the probability of developing AD dementia in mild cognitively impaired individuals within five years, enabling appropriate treatments at an early stage of the disease process and expanding the opportunities for market players. These innovations support broader specimen collection cards industry analysis by enhancing diagnostic accessibility and efficiency.

• Increasing high demands for non-invasive procedures.
• Rising demand for the convenience of usage of diagnostic procedures.
• Increasing demand for sample stability at different temperatures.
• Growing demand for AI-powered tools and software.

The expected issues with maintaining sample integrity and storage are likely to hinder the specimen collection cards market, affecting the accuracy of testing results and requiring the maintenance of sample stability during diagnosis. Furthermore, this technology is susceptible to adverse effects from extreme conditions and environmental influences, such as temperature and humidity, which can lead to chemical reactions and result in altered outcomes. In addition, these tests are time-consuming, and the limited availability of collection devices and testing facilities, as well as the high risk of contamination from various sources, such as chemicals, bacteria, and environmental factors, can lead to inaccurate positive or negativtestts result,s and impropedisposalle of samples can cause health issues to the public, thereby limiting the market growth. These challenges are important considerations in any specimen collection cards market analysis.

The market is expanding because of the growing interest in the healthcare industry in telemedicine implementation and more convenient, safe, and accurate remote healthcare diagnostic tests for infants as well as older individuals. They can be used anytime and anywhere, helping to reduce material, shipping, and storage costs for sample collection. Specimen collection cards serve as an indispensable means in infant screening, providing a streamlined approach to collect blood samples quickly in order to initiate intervention. The growing adoption of paediatric & neonatal testing kits further complements these screening programs by supporting early diagnosis and treatment pathways.

Furthermore, the global focus on preventive healthcare measures for infants, such as required early screening for numerous rare disorders such as spinal muscular atrophy and severe combined immunodeficiency (SCID), acts as a keystone, helping the market's supremacy of specimen collection cards. According to NIH, SMA is a rare disease, and its prevalence is often cited as approximately 10 in 100,000 births, characterized by muscle weakness, which affects shortened life expectancy. In addition, SCID is an inherited primary autoimmune disorder, present by six months of age in infants, leading to early death due to the absence of T and B cell function. 

For instance, in November 2022, the FDA approved PerkinElmer’s EONIS SCID-SMA assay kit for diagnostic and detection of SMA and SCID in newborns by using a single dried blood spot sample based on a real-time polymerase system using EONIS Analysis Software and EONIS DNA Extraction kit, contributing to increasing utilization of specimen collection cards in hospitals and clinics. In addition, in February 2023, Capitaner launched the Capitaner B50 self-sampling blood collection product, which collects five times more blood than the conventional method. Providing non-invasive procedures and ease of use to implement more types of analysis and widespread adoption of specimen collection cards, and contributing new opportunities for laboratories in low and middle-income countries. These developments strengthen the overall specimen collection cards market outlook.

QIAGEN, PerkinElmer AES, Eastern Business Forms, Inc, ARCHIMEDlife, Ahlstrom, GenTegra, FortiusBio, and CENTOGEN are some of the prominent market players operating in the specimen collection cards market.

North America’s dominance in the specimen collection card market is attributed to its high patient footfall, varied testing requirements, and adherence to quality healthcare facilities. North America accounts for the maximum prevalence of infectious diseases; every year, around 23 million individuals seek clinical treatment, resulting in regular check-ups and early diagnosis awareness related toinfectious diseasese. To get an early diagnosis of infections in the body, blood, urine, and other fluids are used mostly in spot-dried samples, which provides a swift and decentralized diagnostic process, enabling seeking advice at an early point and upsurging the demand for diagnostic testing and disease surveillance, consequently boosting the specimen collection market. The widespread use of collection accessories such as syringes in healthcare settings also supports efficient sample acquisition and handling. In addition, increased centralized testing facilities, larger network integration between customers and market players and R&D activities among research institutes for the development of new specimen collection card technologies and AI-powered products will drive the North American market. This regional dominance contributes significantly to the specimen collection cards market share.

Europe can offer huge growth potential for the specimen collection card market with Finland leading the way. Wide applications in the preservation of DNA samples of plants, fungi, insects, and parasites at average thermal temperatures are driving the specimen collection card market. For instance, in April 2024, Ahlstrom launched Leafsaver, designed to transport DNA from plants, fungi, insects, and parasites without refrigerator preservation, allowing specimen preservation for over twenty years. Thus, reducing logistic cost and environmental impact enables significant advancement in plants and microbial preservation technology and allows scientists to examine the genetic makeup of various species-related diseases in humans, making research institutes key drivers of demand for specimen collection cards in the market. Such developments reflect evolving specimen collection cards market trends.

The rapid prevalence of infectious diseases and regulatory healthcare rules is also boosting demand in Europe. This is expected to create ideal conditions for market expansion. Furthermore, the specimen collection card market is expected to be the most profitable market in the Asia Pacific, owing to the increasing population and increasing purchasing power of customers, which enhances healthcare research, and developing economies such as China, India, and Indonesia are expected to drive the market demand. The growing use of specimen collection solutions across multiple sample types, including those associated with urinary bag-based collection workflows, is further supporting diagnostic accessibility. These factors are expected to support the specimen collection cards market forecast and influence future specimen collection cards market segmentation strategies across regions and end-use applications.

Geographic Coverage of the Report:

• Forward-looking valuation of the specimen collection cards market spans revenue trajectories, unit shipments, CAGR pathways and year-on-year acceleration patterns, enabling stakeholders to interpret decade-long expansion signals and structural demand shifts within diagnostic consumables ecosystems.
• Segmentation architecture across the specimen collection cards market distinguishes product formats, application-driven usage settings and end-user adoption layers, revealing nuanced performance variations across laboratory and clinical workflows.
• Demand behavior in the specimen collection cards market is shaped by DROT forces, including diagnostic expansion, raw material traceability challenges, reimbursement pressures and evolving clinical sampling protocols influencing procurement decisions.
• Regional stratification of the specimen collection cards market highlights differentiated adoption across North America, Europe, Asia-Pacific and emerging economies, alongside country-level forecasts that map infrastructure readiness and diagnostic penetration trends.
• Competitive mapping within the specimen collection cards market evaluates enterprise positioning, market share distribution, consolidation intensity and merger & acquisition activity reshaping supplier ecosystems and strategic alliances.
• Pricing structures across the specimen collection cards market intersect with supply chain efficiencies, value chain integration and multi-channel distribution strategies spanning institutional procurement and direct laboratory sales models.
• Regulatory frameworks influencing the specimen collection cards market align with quality compliance mandates, material safety standards and evolving diagnostic approvals, while innovation pipelines and parent market dynamics steer product modernization trends.